462 related articles for article (PubMed ID: 32554923)
1. The complement system in COVID-19: friend and foe?
Java A; Apicelli AJ; Liszewski MK; Coler-Reilly A; Atkinson JP; Kim AH; Kulkarni HS
JCI Insight; 2020 Aug; 5(15):. PubMed ID: 32554923
[TBL] [Abstract][Full Text] [Related]
2. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection.
Ramlall V; Thangaraj PM; Meydan C; Foox J; Butler D; Kim J; May B; De Freitas JK; Glicksberg BS; Mason CE; Tatonetti NP; Shapira SD
Nat Med; 2020 Oct; 26(10):1609-1615. PubMed ID: 32747830
[TBL] [Abstract][Full Text] [Related]
3. Severe COVID-19: what have we learned with the immunopathogenesis?
Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M
Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761
[TBL] [Abstract][Full Text] [Related]
4. Neutrophils and Contact Activation of Coagulation as Potential Drivers of COVID-19.
Busch MH; Timmermans SAMEG; Nagy M; Visser M; Huckriede J; Aendekerk JP; de Vries F; Potjewijd J; Jallah B; Ysermans R; Oude Lashof AML; Breedveld PH; van de Poll MCG; van de Horst ICC; van Bussel BCT; Theunissen ROMFIH; Spronk HMH; Damoiseaux JGMC; Ten Cate H; Nicolaes GAF; Reutelingsperger CP; van Paassen P
Circulation; 2020 Nov; 142(18):1787-1790. PubMed ID: 32946302
[No Abstract] [Full Text] [Related]
5. COVID-19: Complement, Coagulation, and Collateral Damage.
Lo MW; Kemper C; Woodruff TM
J Immunol; 2020 Sep; 205(6):1488-1495. PubMed ID: 32699160
[TBL] [Abstract][Full Text] [Related]
6. Rationale for targeting complement in COVID-19.
Polycarpou A; Howard M; Farrar CA; Greenlaw R; Fanelli G; Wallis R; Klavinskis LS; Sacks S
EMBO Mol Med; 2020 Aug; 12(8):e12642. PubMed ID: 32559343
[TBL] [Abstract][Full Text] [Related]
7. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients.
Holter JC; Pischke SE; de Boer E; Lind A; Jenum S; Holten AR; Tonby K; Barratt-Due A; Sokolova M; Schjalm C; Chaban V; Kolderup A; Tran T; Tollefsrud Gjølberg T; Skeie LG; Hesstvedt L; Ormåsen V; Fevang B; Austad C; Müller KE; Fladeby C; Holberg-Petersen M; Halvorsen B; Müller F; Aukrust P; Dudman S; Ueland T; Andersen JT; Lund-Johansen F; Heggelund L; Dyrhol-Riise AM; Mollnes TE
Proc Natl Acad Sci U S A; 2020 Oct; 117(40):25018-25025. PubMed ID: 32943538
[TBL] [Abstract][Full Text] [Related]
8. Complement activation in patients with COVID-19: A novel therapeutic target.
Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Panigada M; Aliberti S; Blasi F; Tedesco F; Peyvandi F
J Allergy Clin Immunol; 2020 Jul; 146(1):215-217. PubMed ID: 32417135
[No Abstract] [Full Text] [Related]
9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
10. The case of complement activation in COVID-19 multiorgan impact.
Noris M; Benigni A; Remuzzi G
Kidney Int; 2020 Aug; 98(2):314-322. PubMed ID: 32461141
[TBL] [Abstract][Full Text] [Related]
11. Could severe COVID-19 be considered a complementopathy?
Chatzidionysiou K; Svenungsson E; Faustini F
Lupus Sci Med; 2020 May; 7(1):. PubMed ID: 32430402
[No Abstract] [Full Text] [Related]
12. Urgent avenues in the treatment of COVID-19: Targeting downstream inflammation to prevent catastrophic syndrome.
Quartuccio L; Semerano L; Benucci M; Boissier MC; De Vita S
Joint Bone Spine; 2020 May; 87(3):191-193. PubMed ID: 32321634
[No Abstract] [Full Text] [Related]
13. COVID-19-Associated Coagulopathy: An Exacerbated Immunothrombosis Response.
Jayarangaiah A; Kariyanna PT; Chen X; Jayarangaiah A; Kumar A
Clin Appl Thromb Hemost; 2020; 26():1076029620943293. PubMed ID: 32735131
[TBL] [Abstract][Full Text] [Related]
14. Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
Mastellos DC; Pires da Silva BGP; Fonseca BAL; Fonseca NP; Auxiliadora-Martins M; Mastaglio S; Ruggeri A; Sironi M; Radermacher P; Chrysanthopoulou A; Skendros P; Ritis K; Manfra I; Iacobelli S; Huber-Lang M; Nilsson B; Yancopoulou D; Connolly ES; Garlanda C; Ciceri F; Risitano AM; Calado RT; Lambris JD
Clin Immunol; 2020 Nov; 220():108598. PubMed ID: 32961333
[TBL] [Abstract][Full Text] [Related]
15. Current Overview on Hypercoagulability in COVID-19.
Singhania N; Bansal S; Nimmatoori DP; Ejaz AA; McCullough PA; Singhania G
Am J Cardiovasc Drugs; 2020 Oct; 20(5):393-403. PubMed ID: 32748336
[TBL] [Abstract][Full Text] [Related]
16. Myocardial injury and COVID-19: Possible mechanisms.
Babapoor-Farrokhran S; Gill D; Walker J; Rasekhi RT; Bozorgnia B; Amanullah A
Life Sci; 2020 Jul; 253():117723. PubMed ID: 32360126
[TBL] [Abstract][Full Text] [Related]
17. The trinity of COVID-19: immunity, inflammation and intervention.
Tay MZ; Poh CM; Rénia L; MacAry PA; Ng LFP
Nat Rev Immunol; 2020 Jun; 20(6):363-374. PubMed ID: 32346093
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 cytokine storm: the interplay between inflammation and coagulation.
Jose RJ; Manuel A
Lancet Respir Med; 2020 Jun; 8(6):e46-e47. PubMed ID: 32353251
[No Abstract] [Full Text] [Related]
19. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.
Debnath M; Banerjee M; Berk M
FASEB J; 2020 Jul; 34(7):8787-8795. PubMed ID: 32525600
[TBL] [Abstract][Full Text] [Related]
20. Endothelial Dysfunction in COVID-19: Lessons Learned from Coronaviruses.
Gavriilaki E; Anyfanti P; Gavriilaki M; Lazaridis A; Douma S; Gkaliagkousi E
Curr Hypertens Rep; 2020 Aug; 22(9):63. PubMed ID: 32852642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
